Azurity Pharmaceuticals has announced that the US Food and Drug Administration (FDA) has approved XIFYRM (meloxicam injection), an IV non-steroidal anti-inflammatory drug (NSAID) that offers once daily dosing.

XIFYRM is indicated for use in adults for the management of moderate-to-severe pain, alone or in combination with non-NSAID analgesics. XIFYRM provides a non-opioid analgesic in a 30mg/mL vial for IV bolus injection over 15 seconds. Because of delayed onset of analgesia, XIFYRM alone is not recommended for use when rapid onset of analgesia is required, the company said in a statement.

Ron Scarboro, CEO at Azurity Pharmaceuticals said, “XIFYRM demonstrates our commitment to improving patient care by providing an alternate dosage form for pain management. XIFYRM addresses an important clinical need, especially for patients requiring a non-opioid component to multimodal analgesia strategies.”